Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $88.17

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $88.75.

Several equities analysts have commented on ARWR shares. Sanford C. Bernstein upped their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Weiss Ratings cut Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Finally, Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the sale, the insider owned 226,958 shares in the company, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. Arrowstreet Capital Limited Partnership boosted its holdings in Arrowhead Pharmaceuticals by 3,142.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after purchasing an additional 2,017,489 shares in the last quarter. Norges Bank acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $113,159,000. Fred Alger Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock worth $121,693,000 after buying an additional 1,526,164 shares during the period. Renaissance Technologies LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth approximately $64,988,000. Finally, Deerfield Management Company L.P. bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $34,249,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $74.52 on Wednesday. The company’s fifty day moving average is $77.41 and its two-hundred day moving average is $69.57. Arrowhead Pharmaceuticals has a 52-week low of $14.30 and a 52-week high of $87.83. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market capitalization of $10.50 billion, a price-to-earnings ratio of -34.66 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. During the same quarter in the prior year, the business earned $2.75 earnings per share. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis. Equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.07 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.